Cargando…

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans

BACKGROUND: The high cost and prolonged timeline of new drug discovery and development are major roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most common cause of fatal fungal infections in humans and costs $2–4 billion do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kevin, Zilbermintz, Leeor, Martchenko, Mikhail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462072/ https://www.ncbi.nlm.nih.gov/pubmed/26054754 http://dx.doi.org/10.1186/s12941-015-0090-4

Ejemplares similares

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Cross-inhibition of pathogenic agents and the host proteins they exploit
por: Zilbermintz, Leeor, et al.
Publicado: (2016)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

Cancer drugs inhibit morphogenesis in the human fungal pathogen, Candida albicans
por: Routh, Madhushree M, et al.
Publicado: (2014)

In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
por: Mee-udorn, Pitchayathida, et al.
Publicado: (2023)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Candida albicans: A Major Fungal Pathogen of Humans
por: Richardson, Jonathan P.
Publicado: (2022)

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
por: James, Jenna R., et al.
Publicado: (2023)

Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
por: Peele, K.Abraham, et al.
Publicado: (2021)

Repurposing Clinically Approved Drugs for the Treatment of Bacillus cereus, a Surrogate for Bacillus anthracis
por: Amakawa, Masami, et al.
Publicado: (2020)

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study
por: Akinlalu, Alfred Olaoluwa, et al.
Publicado: (2021)

Chemogenomic Profiling of the Fungal Pathogen Candida albicans
por: Chen, Yaolin, et al.
Publicado: (2018)

Transcriptomics of the Fungal Pathogens, Focusing on Candida albicans
por: Rupp, Steffen
Publicado: (2008)

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)

Oxidative Stress Responses in the Human Fungal Pathogen, Candida albicans
por: da Silva Dantas, Alessandra, et al.
Publicado: (2015)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
por: Benedict, Ashwini, et al.
Publicado: (2015)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
por: Jones, Dylan, et al.
Publicado: (2022)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Regulation of phenotypic transitions in the fungal pathogen Candida albicans
por: Huang, Guanghua
Publicado: (2012)

Glucanase Induces Filamentation of the Fungal Pathogen Candida albicans
por: Xu, Hongbin, et al.
Publicado: (2013)

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Rac1 Dynamics in the Human Opportunistic Fungal Pathogen Candida albicans
por: Vauchelles, Romain, et al.
Publicado: (2010)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014)

Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential
por: Lo, Yu-Chen, et al.
Publicado: (2017)

FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy
por: Zali, Hakimeh, et al.
Publicado: (2019)

Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats
por: Zulfiqar, Zikra, et al.
Publicado: (2020)

Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
por: Kulkarni, Ameya S., et al.
Publicado: (2022)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

Comparative Phenotypic Analysis of the Major Fungal Pathogens Candida parapsilosis and Candida albicans
por: Holland, Linda M., et al.
Publicado: (2014)

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
por: Dittmar, Mark, et al.
Publicado: (2021)

In Silico Drug Repurposing Approach: Investigation of Mycobacterium tuberculosis FadD32 Targeted by FDA-Approved Drugs
por: Ngidi, Nolwazi Thobeka Portia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8jscm6hl2b8uo85c2n0mi0fnf4